Highlights from the 1st European cancer dependency map symposium and workshop
Authors:
- 24 July 2023
- journal article
- editorial
- Published by Wiley in FEBS Letters
- Vol. 597 (15) , 1921-1927
Abstract
The systematic identification of tumour vulnerabilities through perturbational experiments on cancer models, including genome editing and drug screens, is playing a crucial role in combating cancer. This collective effort is known as the Cancer Dependency Map (DepMap). The 1st European Cancer Dependency Map Symposium (EuroDepMap), held in Milan last May, featured talks, a roundtable discussion, and a poster session, showcasing the latest discoveries and future challenges related to the DepMap. The symposium aimed to facilitate interactions among participants across Europe, encourage idea exchange with leading experts, and present their work and future projects. Importantly, it sparked discussions on future endeavours, such as screening more complex cancer models and accounting for tumour evolution.Keywords
This publication has 33 references indexed in Scilit:
- Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targetingBMC Genomics, 2018
- Application of CRISPR-Cas9 Based Genome-Wide Screening Approaches to Study Cellular Signalling MechanismsInternational Journal of Molecular Sciences, 2018
- PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screensNucleic Acids Research, 2017
- Defining a Cancer Dependency MapCell, 2017
- A Landscape of Pharmacogenomic Interactions in CancerCell, 2016
- MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cellsScience, 2016
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006